arrow_back Trending Legislation
Share share

Transfer of Civil Penalties to Pediatric Research Funding

This act requires civil monetary sanctions collected from specific entities in the pharmaceutical, medical device, dietary supplement, and cosmetic sectors to be transferred to the Pediatric Research Initiative Fund. These funds are designated to support research on pediatric cancer and other childhood diseases at the National Institutes of Health (NIH). The bill also mandates the NIH Director to coordinate research and prioritize projects that do not duplicate existing activities.
Key points
Redirects civil penalties from drug, supplement, and cosmetic manufacturers to a research fund.
Funds research into pediatric cancer and diseases at the NIH.
Requires prioritization of research that avoids duplicating existing NIH activities.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Gabriella Miller Kids First Research Act 2.0
Print number: S 1521
Sponsor: Sen. Kaine, Tim [D-VA]
Process start date: 2021-04-29
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Transfer of Civil Penalties to Pediatric Research Funding

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1521.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-29.

What are the main provisions?

Key points include:

  • Redirects civil penalties from drug, supplement, and cosmetic manufacturers to a research fund.
  • Funds research into pediatric cancer and diseases at the NIH.
  • Requires prioritization of research that avoids duplicating existing NIH activities.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Kaine, Tim [D-VA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

Analysis and Potential Impact of S 1521

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health